Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab

BACKGROUND: Up to 30% of patients with food allergies have clinical reactivity to more than one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under investigation. Pilot data have shown that omalizumab may hasten the ability to tolerate over 4 g of food allergen prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Bégin, Philippe, Dominguez, Tina, Wilson, Shruti P, Bacal, Liane, Mehrotra, Anjuli, Kausch, Bethany, Trela, Anthony, Tavassoli, Morvarid, Hoyte, Elisabeth, O’Riordan, Gerri, Blakemore, Alanna, Seki, Scott, Hamilton, Robert G, Nadeau, Kari C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936817/
https://www.ncbi.nlm.nih.gov/pubmed/24576338
http://dx.doi.org/10.1186/1710-1492-10-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936817/
https://www.ncbi.nlm.nih.gov/pubmed/24576338
http://dx.doi.org/10.1186/1710-1492-10-7

Ejemplares similares